Hideki Shimodaira

2.7k total citations · 1 hit paper
56 papers, 1.8k citations indexed

About

Hideki Shimodaira is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Hideki Shimodaira has authored 56 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 25 papers in Pulmonary and Respiratory Medicine and 19 papers in Molecular Biology. Recurrent topics in Hideki Shimodaira's work include Colorectal Cancer Treatments and Studies (19 papers), Genetic factors in colorectal cancer (14 papers) and Gastric Cancer Management and Outcomes (13 papers). Hideki Shimodaira is often cited by papers focused on Colorectal Cancer Treatments and Studies (19 papers), Genetic factors in colorectal cancer (14 papers) and Gastric Cancer Management and Outcomes (13 papers). Hideki Shimodaira collaborates with scholars based in Japan, United States and Canada. Hideki Shimodaira's co-authors include Chikashi Ishioka, Richard D. Kolodner, Masanobu Takahashi, Takao Suzuki, Jean Y. J. Wang, Ryunosuke Kanamaru, Tomohiro Nishina, Satoshi Morita, Kazumasa Fujitani and Shuichi Hironaka and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Hideki Shimodaira

54 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial

2013 351 citations Shuichi Hironaka, Shinya Ueda et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Hideki Shimodaira

Since Specialization

Citations

This map shows the geographic impact of Hideki Shimodaira's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hideki Shimodaira with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hideki Shimodaira more than expected).

Fields of papers citing papers by Hideki Shimodaira

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hideki Shimodaira. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hideki Shimodaira. The network helps show where Hideki Shimodaira may publish in the future.

Co-authorship network of co-authors of Hideki Shimodaira

This figure shows the co-authorship network connecting the top 25 collaborators of Hideki Shimodaira. A scholar is included among the top collaborators of Hideki Shimodaira based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hideki Shimodaira. Hideki Shimodaira is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cisplatin Plus Capecitabine After Adjuvant S-1 in Metastatic Gastric Cancer: A Phase II T-CORE1102 Trial 2022 ·Anticancer Research ·Takashi Yoshioka, Masanobu Takahashi, Yasuhiro Sakamoto, Akira Okita, Tadahisa Fukui, (unknown), (unknown), Hiroo Imai, Hisatsugu Ohori, Hidekazu Shirota, Natsuko Chiba, (unknown), Takashi Nomura, Norimasa Fukushima, Takuhiro Yamaguchi, Hideki Shimodaira, Chikashi Ishioka	1
2	A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer 2018 ·European Journal of Cancer ·Hideaki Bando, Hideki Shimodaira, Kazumasa Fujitani, Atsuo Takashima, Kensei Yamaguchi, Norisuke Nakayama, Takehiro Takahashi, Eiji Oki, Mizutomo Azuma, Tomohiro Nishina, Shuichi Hironaka, Yoshito Komatsu, Kohei Shitara	49
3	Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial 2017 ·The Lancet. Gastroenterology & hepatology ·Kohei Shitara, Atsuo Takashima, Kazumasa Fujitani, Keisuke Koeda, Hiroki Hara, Norisuke Nakayama, Shuichi Hironaka, Kazuhiro Nishikawa, Yoichi Makari, Kenji Amagai, Shinya Ueda, Kazuhiro Yoshida, Hideki Shimodaira, Tomohiro Nishina, Masahiro Tsuda, Yukinori Kurokawa, Takao Tamura, Yasutsuna Sasaki, Satoshi Morita, Wasaburo Koizumi	139
4	Treatment outcome according to tumor RAS mutation status in TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer 2017 ·Annals of Oncology ·Yoshito Komatsu, Atsuo Takashima, Tadamichi Denda, Makio Gamoh, Ichiro Iwanaga, Hideki Shimodaira, Masato Nakamura, Tatsuro Yamaguchi, (unknown), Kouji Kobayashi, Masahiro Tsuda, (unknown), Hideo Baba, Masanori Kotake, Chikashi Ishioka, Akinori Sato, Satoshi Yuki, Satoshi Morita, S Takahashi, K. Shimada	4
5	microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer 2017 ·BMC Cancer ·Hidekazu Takahashi, Masanobu Takahashi, Shinobu Ohnuma, Michiaki Unno, Yuki Yoshino, Kota Ouchi, Shin Takahashi, Yasuhide Yamada, Hideki Shimodaira, Chikashi Ishioka	30
6	Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma 2016 ·Chemotherapy ·Hiroo Imai, Keigo Komine, Shin Takahashi, Ken Saijo, (unknown), Akihiro Kobayashi, Akira Okita, (unknown), (unknown), Masahiro Takahashi, Takayuki Oishi, Hidekazu Shirota, Masanobu Takahashi, Hideki Shimodaira, Chikashi Ishioka	10
7	Successful sequential treatment of a patient with advanced gastrointestinal stromal tumor using four different molecularly targeted drugs 2016 ·International Cancer Conference Journal ·Shunsuke Sugiyama, (unknown), Masanobu Takahashi, Keigo Komine, Hiroo Imai, Ken Saijo, Masahiro Takahashi, Hidekazu Shirota, Shin Takahashi, Hideki Shimodaira, Chikashi Ishioka	0
8	OLA1 gene sequencing in patients with BRCA1/2 mutation-negative suspected hereditary breast and ovarian cancer 2016 ·Breast Cancer ·Masanobu Takahashi, Natsuko Chiba, Hideki Shimodaira, Yuki Yoshino, Takahiro Mori, (unknown), Tadashi Nomizu, Chikashi Ishioka	7
9	CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer 2016 ·International Journal of Clinical Oncology ·Xiaofei Zhang, Hideki Shimodaira, (unknown), Keigo Komine, Hidekazu Takahashi, Kota Ouchi, Masahiro Inoue, Masanobu Takahashi, Shin Takahashi, Chikashi Ishioka	21
10	A retrospective analysis of the efficacy and safety of everolimus in patients with unresectable tumor 2015 ·Annals of Oncology ·Takayuki Oishi, Masanobu Takahashi, (unknown), Hidekazu Takahashi, (unknown), Masahiro Takahashi, Takahiro Mori, (unknown), Hideki Shimodaira, Chikashi Ishioka	0
11	Phase II Trial of Cetuximab plus Irinotecan for Oxaliplatin- and Irinotecan-Based Chemotherapy-Refractory Patients with Advanced and/or Metastatic Colorectal Cancer: Evaluation of Efficacy and Safety Based on <b><i>KRAS</i></b> Mutation Status (T-CORE0801) 2014 ·Oncology ·(unknown), Hideki Shimodaira, Makio Gamoh, Hideaki Ando, (unknown), Takeshi Suto, Shin Takahashi, Yuichi Kakudo, Kenji Amagai, Takahiro Mori, Mika Watanabe, Takuhiro Yamaguchi, Shunsuke Kato, Chikashi Ishioka	16
12	Upper Arm Central Venous Port Implantation: A 6-Year Single Institutional Retrospective Analysis and Pictorial Essay of Procedures for Insertion 2014 ·PLoS ONE ·(unknown), Shin Takahashi, Yuichi Kakudo, Masanobu Takahashi, Hideki Shimodaira, Shunsuke Kato, Chikashi Ishioka	28
13	KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin-or irinotecan-based treatment 2014 ·Molecular and Clinical Oncology ·(unknown), Hideki Shimodaira, Mika Watanabe, Takao Suzuki, (unknown), Masanobu Takahashi, Keigo Komine, Shunsuke Kato, Chikashi Ishioka	5
14	Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3‐kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3‐kinase dual inhibitors 2012 ·Cancer Science ·Ken Saijo, Tadashi Katoh, Hideki Shimodaira, Akifumi Oda, Ohgi Takahashi, Chikashi Ishioka	41
15	Aberrant splicing caused by a MLH1 splice donor site mutation found in a young Japanese patient with Lynch syndrome 2012 ·Familial Cancer ·Masanobu Takahashi, Yoichi Furukawa, Hideki Shimodaira, (unknown), Takuya Moriya, Yoshihiro Moriya, Yusuke Nakamura, Chikashi Ishioka	2
16	Safety Verification Trials of mFOLFIRI and Sequential IRIS + Bevacizumab as First- or Second-Line Therapies for Metastatic Colorectal Cancer in Japanese Patients 2012 ·Oncology ·Shunsuke Kato, (unknown), Makio Gamoh, Takuhiro Yamaguchi, (unknown), Hideki Shimodaira, Shin Takahashi, Takahiro Mori, Hisatsugu Ohori, (unknown), Takao Suzuki, Satoshi Kato, (unknown), Yuka Sasaki, Takashi Yoshioka, Chikashi Ishioka	9
17	A randomized pilot study comparing safety and efficacy of irinotecan plus S-1 (IRIS) plus bevacizumab (BV) and modified (m) FOLFIRI plus BV in patients (pts) with metastatic colorectal cancer (mCRC): First report of T-CORE0702. 2011 ·Journal of Clinical Oncology ·Shunsuke Kato, (unknown), Makio Gamoh, Takuhiro Yamaguchi, (unknown), Yu Sasaki, Shin Takahashi, Hideki Shimodaira, Takashi Yoshioka, Chikashi Ishioka	2
18	Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation 2006 ·International Journal of Clinical Oncology ·Takashi Yoshioka, (unknown), Shunsuke Kato, Natsuko Chiba, Shukichi Miyazaki, Kenji Nemoto, Hiroyuki Shibata, Hideki Shimodaira, (unknown), Yuichi Kakudo, Yuh Sakata, Chikashi Ishioka	19
19	Analysis of the human APC mutation spectrum in a saccharomyces cerevisiae strain with a mismatch repair defect 2002 ·International Journal of Cancer ·Kazunori Otsuka, Takao Suzuki, Hiroyuki Shibata, (unknown), (unknown), Hideki Shimodaira, Ryunosuke Kanamaru, Chikashi Ishioka	3
20	Functional analysis of human MLH1 mutations in Saccharomyces cerevisiae 1998 ·Nature Genetics ·Hideki Shimodaira, (unknown), Hiroyuki Shibata, Takao Suzuki, Paolo Radice, Ryunosuke Kanamaru, Stephen Friend, Richard D. Kolodner, Chikashi Ishioka	111

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact